Q4 2024 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vanda Pharmaceuticals Inc (VNDA) reported strong revenue growth for Fanapt, with new patient starts increasing by over 160% in the fourth quarter of 2024 compared to the same period in 2023.
- The company initiated a Phase III program for the long-acting injectable formulation of Fanapt, which could drive future growth in their psychiatry portfolio.
- Vanda Pharmaceuticals Inc (VNDA) launched PONVORY for the treatment of multiple sclerosis, contributing to revenue diversification.
- The company entered into an exclusive global license agreement with AnaptysBio for imsidolimab, an IL-36 receptor antagonist, which could expand their anti-inflammatory portfolio.
- Vanda Pharmaceuticals Inc (VNDA) is targeting total annual revenue in excess of $1 billion by 2030, with significant contributions expected from their psychiatry portfolio.
- HETLIOZ net product sales decreased by 23% in 2024 compared to 2023 due to continued generic competition in the US.
- Vanda Pharmaceuticals Inc (VNDA) recorded a net loss of $18.9 million for the full year 2024, compared to a net income of $2.5 million in 2023.
- Operating expenses increased by $32.8 million in 2024, primarily driven by higher SG&A expenses related to commercial launches and legal activities.
- The company is facing challenges with an IRB objecting to a placebo-controlled design for a schizophrenia maintenance study, potentially delaying the Fanapt long-acting injectable program.
- Vanda Pharmaceuticals Inc (VNDA) did not provide 2025 cash guidance due to uncertainties in determining the right size for direct-to-consumer advertising investments.
Hello and thank you for standing by. This time I'd like to welcome you to the Q4 2024 Vanda Pharmaceuticals Inc earnings conference call. (Operator Instructions)
I would now like to turn the conference over to Mr. Kevin Moran, Vanda's Chief Financial Officer. Please go ahead, sir.
Thank you, Jericho. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals fourth-quarter and full-year 2024 performance. Our fourth-quarter and full-year 2024 results were released this afternoon and are available on the SEC's EDGAR system and on our website www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.
Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board; and Tim Williams, our General Counsel. Following my introductory remarks, Mihael will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
